

Almirall announces partnership with the Centre for Genomic Regulation (CRG) to identify biomarkers for novel atopic dermatitis treatments

- The collaboration aims to create advanced atopic dermatitis (AD) disease models to develop new treatment options
- An ongoing research collaboration between the two partners is aimed at developing and characterizing novel preclinical models as the basis for developing new treatment options for non-melanoma skin cancer (NMSC)

BARCELONA, Spain. February 8th, 2023 – Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today a **new research partnership with the Centre for Genomic Regulation (CRG)**, an international biomedical research institute headquartered in Barcelona. The collaboration aims to identify molecular pathways and biomarkers specific to atopic dermatitis (AD). New insights into the mechanism of action of this complex disease has the potential to enable the development of novel treatment options.

The research objectives of this collaboration include the characterization of more detailed AD disease models with high physiological relevance and disease predictability. The partnership aims to **identify new therapeutic approaches for the treatment of AD as a starting point for novel drug discovery projects.**

Almirall will contribute its extensive experience in model development, sample preparation of *in vitro* and *in vivo* AD models, as well as *tissue* samples, transcriptomics¹ and data analysis. **The CRG will provide expertise in proteomics²** to identify potential drug targets for AD, thus broadening the scope of treatment options for this disease.

“We are pleased with the recent advancements in the treatment options for atopic dermatitis. However, we are also looking ahead to identify scientific and technological innovations that could enable the next level of treatment options to serve patients even better in the future. This collaboration allows us to combine our expertise in medical dermatology with the capabilities of the CRG’s proteomics unit to better understand this complex disease and explore novel treatment opportunities for AD,” states **Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall.**

“Proteomics technologies are used in many translational research projects both for diagnosis and to understand disease mechanisms. Collaborating with a recognized company such as Almirall will allow us to delve deeper into the pathogenesis of atopic dermatitis, which can provide the basis to further help patients suffering from this disease,” says **Dr. Eduard Sabidó, Head of the Joint CRG/UPF Proteomics Unit (ICTS OmicsTech).**

¹ Transcriptomics is the study of the whole transcriptome (all the RNA transcripts) of a cell or a tissue.

² Proteomics is the study of the interactions, function, composition, and structures of proteins and their cellular activities.

Almirall and the CRG have previously already established a [collaboration in 2023 to develop and characterize novel preclinical models](#) that will help identify new treatments for non-melanoma skin cancer (NMSC).

This project will have an initial duration of two years and is partially funded by the Instituto de Salud Carlos III (ISCIII) and the Centro de Desarrollo Tecnológico e Innovación (CDTI) (Spanish Ministry of Science) with Next Generation Europe funds.



About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: *to transform the patients' world by helping them realize their hopes and dreams for a healthy life*. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Almirall (total revenue in 2022: €878.5 MM, 1800 employees globally) has a direct presence in 21 countries and affiliates in over 70 others.

Media contact Almirall

Tinkle
Sergi Garcia
sergi.garcia@tinkle.es
Phone: (+34) 627 377 980

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 30 87

Corporate Communications contact

Almirall
Mar Ramírez
mar.ramirez@almirall.com
Phone: (+34) 659 614 173

About CRG

The CRG is a biomedical research centre located in Barcelona. Created in December 2000, the CRG is home to an interdisciplinary research team of more than four hundred scientists focused on understanding the complexity of life, from the genome to the cell and a complete organism. The CRG is a research centre with a unique research model focused on recruiting internationally recognized leaders in the field. The CRG is a member of the Barcelona Institute of Science and Technology (BIST) and is a CERCA centre, part of the Generalitat de Catalunya research ecosystem.

Legal warning of Almirall

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.